Leuprolide Completed Phase 4 Trials for Prostate Cancer Treatment

clinicaltrials.gov IdentifierTitleDrugs
NCT03035032A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
NCT01136226Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01511874Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT00220194A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer